Stringent allele/epitope requirements for MART-1/Melan A immunodominance: Implications for peptide-based immunotherapy

Journal of Immunology

Volumn 161, Issue 2, 1998, Pages 877-889

  Bettinotti, Maria P ^a   Kim, Christina J ^b   Lee, Kang Hun ^a   Roden, Matthew ^b   Cormier, Janice N ^b   Panelli, Monica ^b   Parker, Kenneth K ^c   Marincola, Francesco M ^a,b  

^a CLINICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN; T LYMPHOCYTE RECEPTOR;

ALLELE; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE;

ALLELES; AMINO ACID SEQUENCE; ANTIBODIES, NEOPLASM; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FOWLPOX VIRUS; HLA-DQ ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

EID: 0032528404     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
2. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
3. Marincola, F. M., P. Shamamian, L. Rivoltini, M. L. Salgaller, J. Reid, N. P. Restifo, T. B. Simonis, D. Venzon, D. E. White, and D. R. Parkinson. 1996. HLA associations in the anti-tumor response against malignant melanoma. J. Immunother. 18:242.
4. Player, M. A., K. C. Barracchini, T. B. Simonis, L. Rivoltini, F. Arienti, C. Castelli, A. Mazzocchi, F. Belli, and F. M. Marincola. 1996. Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J. Immunother. 19:357.
5. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. W. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95:341.
6. Cormier, J. N., M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:37.
7. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749.
8. del Guercio, M. F., J. Sidney, G. Hermanson, C. Perez, H. M. Grey, R. T. Kubo, and A. Sette. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154:685.
9. Rivoltini, L., D. J. Loftus, K. Barracchini, F. Arienti, A. Mazzocchi, W. E. Biddison, M. L. Salgaller, E. Appella, G. Parmiani, and F. M. Marincola. 1996. Binding and presentation of peptides derived from melanoma antigens MART-1 and gp100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J. Immunol. 156:3882.
10. Sidney, J., H. M. Grey, S. Southwood, E. Cells, P. A. Wentworth, M. F. del Guercio, R. T. Kubo, R. W. Chesnut, and A. Sette. 1996. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum. Immunol. 45:79.
11. Rotzschke, O., K. Falk, S. Stevanovic, G. Jung, and H. G. Rammensee. 1992. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur. J. Immunol. 22:2453.
12. Skipper, J. C., D. J. Kittlesen, R. C. Hendrickson, D. D. Deacon, N. L. Harthun, S. N. Wagner, D. F. Hunt, V. H. Engelhard, and C. L. Slingluff, Jr. 1996. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/ gp100. J. Immunol. 157:5027.
13. Kang, X., Y. Kawakami, M. el-Gamil, R. Wang, K. Sakaguchi, J. R. Yannelli, E. Appella, S. A. Rosenberg, and P. F. Robbins. 1995. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol. 155:1343.
14. Brichard, V. G., J. Herman, A. Van Pel, C. Wildmann, B. Gaugler, T. Wolfel, T. Boon, and B. Lethe. 1996. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol. 26:224.
15. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921.
16. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
17. Kim, C. J., D. R. Parkinson, and F. M. Marincola. 1998. Immunodominance across HLA polymorphism: implications for cancer immunotherapy. J. Immunother. 21:1.
18. Kim, C. J., T. Prevette, J. Cormier, W. Overwijk, M. Roden, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Dendritic cells infected with pox-viruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother. 20:276.
19. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J. Immunol. 157:2539.
20. Cerundolo, V., J. Alexander, K. Anderson, C. Lamb, P. Cresswell, A. McMichael, F. Gotch, and A. Townsend. 1990. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 345:449.
21. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443.
22. Moss, D. J., I. S. Misko, S. R. Burrows, K. Burman, R. McCarthy, and T. B. Sculley. 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719.
23. Milford, E. L., L. J. Kennedy, S. Y. Yang, B. Dupont, J.-M. Lalouel, and E. J. Yunis. 1989. Serological characterization of the reference panel of B-lymphoblastoid cell lines for factors of the HLA system. In Immunobiology of HLA, Vol 1: Histocompatibility Testing 1987, 1st Ed. B. Dupont, ed. Springer, New York, p. 19.
24. Marincola, F. M., P. Shamamian, R. B. Alexander, J. R. Gnarra, R. L. Turetskaya, S. A. Nedospasov, T. B. Simonis, J. K. Taubenberger, J. Yannelli, A. Mixon, and N. P. Restifo, M. Herlyn, and S. A. Rosenberg. 1994. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 153:1225.
25. Rivoltini, L., K. C. Baracchini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N. P. Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, and F. M. Marincola. 1995. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res. 55:3149.
26. Miller, S. A., D. D. Dykes, and H. F. Polesky. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
27. Bettinotti, M., Y. Mitsuishi, K. Bibee, M. Lau, and P. I. Terasaki. 1997. Comprehensive method for the typing of HLA-A, B and C alleles by direct sequencing of PCR products obtained from genomic DNA. J. Immunother. 20:425.
28. Bettinotti, M. P., Y. Mitsuishi, M. Lau, H. Silver, A. Spence, and P. I. Terasaki. 1996. HLA-A* 1104: a new allele found in a Laotian family. Tissue Antigens 48:717.
29. Bodmer, J. G., S. G. Marsh, E. D. Albert, W. F. Bodmer, R. E. Bontrop, D. Charron, B. Dupont, H. A. Erlich, R. Fauchet, B. Mach, W. R. Mayr, P. Parham, T. Sasazuki, G. M. Schreuder, J. L. Strominger, A. Svejgaard, and P. I. Terasaki. 1997. Nomenclature for factors of the HLA system, 1996. Tissue Antigens 49-297.
30. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109.
31. O'Neil, B. H., Y. Kawakami, N. P. Restifo, J. R. Bennink, J. W. Yewdell, and S. A. Rosenberg. 1993. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J. Immunol. 151:1410.
32. Kawakami, Y., J. K. Battles, T. Kobayashi, W. Ennis, X. Wang, J. P. Tupesis, F. M. Marincola, P. F. Robbins, V. J. Hearing, M. A. Gonda, and S. A. Rosenberg. 1997. Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J. Immunol. Methods 202:13.
33. Kim, C. J., J. N. Cormier, M. Roden, L. Gritz, G. Mazzara, P. A. Fetsch, Y. M. Hijazi, K.-H. Lee, S. A. Rosenberg, and F. M. Marincola. 1998. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann. Surg. Oncol. 5:64.
34. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol. 157:4079.
35. Riddell, S. R., and P. D. Greenberg. 1994. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr. Top. Microbiol. Immunol. 189:9.
36. Parker, K. C., M. DiBrino, L. Hull, and J. E. Coligan. 1992. The beta 2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. J. Immunol. 149:1896.
37. Lee, K.-H., C. J. Kim, P. A. Zimmerman, and F. M. Marincola. 1997. A new high resolution TCR Vβ screening using RT-PCR and heteroduplex analysis: identification and monitoring of epitope specific CTL. Hum. Immunol. 55:44.
38. Rowen, L., B. F. Koop, and L. Hood. 1996. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 272:1755.
39. Fleischhauer, K., S. Tanzarella, V. Russo, M. L. Sensi, P. van der Bruggen, C. Bordignon, and C. Traversari. 1997. Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J. Immunol. 159:2513.
40. + cytotoxic T lymphocytes. J. Exp. Med. 181:363.
41. van Elsas, A., S. H. van der Burg, C. E. van der Minne, M. Borghi, C. J. Melief, and P. I. Schrier. 1996. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immunol. 26:1683.
42. de Campos-Lima, P.-O., V. Levitsky, M. P. Imreh, R. Gavioli, and M. G. Masucci. 1997. Epitope-specific selection of highly restricted or diverse T cell receptors repertoires in response to persistent infection by Epstein-Barr virus. J. Exp. Med. 186:83.
43. + cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int. J. Cancer 57:56.
44. Gjertson, D. W., L. Geer, S.-H. Lee, J. Kawata, and R. Sutrisno. 1997. Population studies. In HLA 1997, 1st Ed. I. P. Terasaki and D. W. Gjertson, eds. HLA Tissue Typing Laboratory, Los Angeles, CA, p. 171.
45. Simonis, T. B., K. C. Barracchini, J. A. Hackett, D. Maurer, P. Siauw, R. Tonai, and F. M. Marincola. 1997. HLA-A*02 allele frequencies of different ethnic groups. Hum. Immunol. 55:99.
46. Chelvanayagam, G. 1996. A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities. Immunogenetics 45:15.
47. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
48. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643.
49. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, and J. C. Renauld, and T. Boon. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
50. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
51. Wolfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K. H. Meyer zum Buschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759.
52. van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boel, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:3038.
53. Guilloux, Y., S. Lucas, V. G. Brichard, A. Van Pel, C. Viret, E. De Plaen, F. Brasseur, B. Lethe, F. Jotereau, and T. Boon. 1996. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183:1173.
54. Stevens, E. J., L. Jacknin, P. F. Robbins, Y. Kawakami, M. el Gamil, S. A. Rosenberg, and J. R. Yannelli. 1995. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: fine specificity and MART-1 melanoma antigen recognition. J. Immunol. 154:762.
55. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. Salgaller, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1995. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257.
56. Salgaller, M. L., A. Afshar, F. M. Marincola, L. Rivoltini, Y. Kawakami, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55:4972.
57. Marincola, F. M., L. Rivoltini, M. L. Salgaller, M. Player, and S. A. Rosenberg. 1996. Differential anti-MART-1/Melan A CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J. Immunother. 19:266.
58. Cormier, J. N., Y. M. Hijazi, A. Abati, P. Fetsch, M. Bettinotti, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1998. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer. 75:517.
59. Niedermann, G., S. Butz, H. G. Ihlenfeldt, R. Grimm, M. Lucchiari, H. Hoschutzky, G. Jung, B. Mater, and K. Eichmann. 1995. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 2:289.
60. Loftus, D. J., C. Castelli, T. M. Clay, P. Squarcina, F. M. Marincola, M. I. Nishimura, G. Parmiani, E. Appella, and L. Rivoltini. 1996. Identification of epitope mimics recognized by CTL reactive to the metanoma/melanocyte-derived peptide MART-1(27-35). J. Exp. Med. 184:647.
61. Arden, B., S. P. Clark, D. Kabelitz, and T. W. Mak. 1995. Human T-cell receptor variable gene segment families. Immunogenetics 42:455.
62. Parker, K. C., M. A. Bednarek, L. K. Hull, U. Utz, B. Cunningham, H. J. Zweerink, W. E. Biddison, and J. E. Coligan. 1992. Sequence motifs important for peptide binding to the human MHC class I molecule. HLA-A2. J. Immunol. 149:3580.
63. Utz, U., S. Koenig, J. E. Coligan, and W. E. Biddison. 1992. Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. J. Immunol. 149:214.
64. Burrows, S. R., S. J. Rodda, A. Suhrbier, H. M. Geysen, and D. J. Moss. 1992. Specificity of recognition of a cytotoxic T lymphocyte epitope. Em. J. Immunol. 22:191.